Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H21N |
Molecular Weight | 155.2804 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(C)CC1CCCCC1
InChI
InChIKey=JCRIVQIOJSSCQD-UHFFFAOYSA-N
InChI=1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3
Propylhexedrine is considered to be an agonist of alpha-adrenergic receptors. It is effective as a topical vasoconstrictor. The primary medicinal use of Benzedrex (Propylhexedrine inhaler) propylhexedrine is temporary symptomatic relief of nasal decongestion due to colds, allergies and allergic rhinitis. Structurally and pharmacologically related to amphetamine.Exact mechanism of action unknown but thought to be similar to amphetamine. When used as a nasal inhaler for this indication, propylhexedrine reduces nasal airway resistance without producing rebound congestion. Abuse does not occur by nasal inhalation; however, a small amount of abuse of the propylhexedrine containing nasal inhalers occurs by oral ingestion of the contents of the inhaler or by intravenous injection. Propylhexedrine is a central nervous system (CNS) stimulant of low abuse potential, a stimulant of low preference for stimulant abusers compared with amphetamine, methylphenidate, phenmetrazine.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095203 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Benzedrex Approved UseSelf-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other allergies. Reduce swelling and facilitate visualization of nasal and pharyngeal membranes prior to surgery or diagnostic procedures. Open obstructed eustachian ostia in patients with ear inflammation. Launch Date1948 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/monograph/benzedrex.html
The Benzedrex propylhexedrine inhaler delivers 0.4–0.5 mg of the drug in each 800 mL of air. Adult dosage: 2 inhalations (0.4–0.5 mg) in each nostril no more than every 2 hours.
Route of Administration:
Nasal
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29709
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
||
|
CFR |
21 CFR 1308.22
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
||
|
CFR |
21 CFR 341.20
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
PROPYLHEXEDRINE
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
101-40-6
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
3595-11-7
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
SUPERSEDED | |||
|
202-939-3
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105275
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
2305
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
222-741-0
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
ALTERNATIVE | |||
|
DTXSID1023526
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
8792
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | RxNorm | ||
|
C084814
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
m9242
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB10121MIG
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
100000081363
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
C47694
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
566
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
LQU92IU8LL
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
7558
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
m9242
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB06714
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
32410
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY | |||
|
LQU92IU8LL
Created by
admin on Sat Dec 16 16:42:41 GMT 2023 , Edited by admin on Sat Dec 16 16:42:41 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)